Phase III results for Angiomax

The Medicines Co. (MDCO) reported that in the open-label part of its U.S. Phase IIIb/IV REPLACE trial in 1,056 angioplasty patients, patients who received its Angiomax bivalirudin thrombin inhibitor h...